Skip to content

A Double-Blind Randomized Controlled Trial Protocol of Transcutaneous Electrical Acupoint Stimulation for Preventing Post-TURP Complications: The TEAS-PRO Trial

A Double-Blind Randomized Controlled Trial Protocol of Transcutaneous Electrical Acupoint Stimulation for Preventing Post-TURP Complications: The TEAS-PRO Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110428
Enrollment
Unknown
Registered
2025-10-14
Start date
2025-10-15
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Blank control group:Following post-TURP nursing guidelines, routine postoperative care includes the following: 1. Monitoring of Vital Signs and Condition: In the early postoperative period, closely

Sponsors

Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital Yunnan Qujing Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 50–80 years undergoing transurethral resection of the prostate; 2. Requiring continuous bladder irrigation for >=24 hours postoperatively; 3. Development of at least one bladder irrigation-related complication within 48 hours postoperatively; 4. Voluntary participation in the study with signed written informed consent; 5. Preoperative International Prostate Symptom Score (IPSS) >=8 points without concomitant severe bladder dysfunction.

Exclusion criteria

Exclusion criteria: 1. Patients with concurrent urinary tract infections; 2. Patients with a history of neurogenic bladder; 3. Patients with concurrent neurological disorders; 4. Patients with concurrent malignant tumors; 5. Patients with severe cardiopulmonary insufficiency; 6. History of pelvic surgery or lower urinary tract trauma; 7. Patients with cognitive impairment, hemiplegia, or lower limb sensory deficits who cannot cooperate with the study; 8. Patients with skin allergies; 9. Participants who have enrolled in other clinical trials or demonstrate poor compliance.

Design outcomes

Primary

MeasureTime frame
Incidence and Severity of Bladder Spasms;Infection Status;Bleeding condition;

Secondary

MeasureTime frame
Serum/urine inflammatory cytokines, including IL-6 and TNF-a;Neurotransmitters, including substance P and ß-endorphin;Pathological biopsy of the bladder mucosa;

Countries

China

Contacts

Public ContactJiang Zhitian

Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital Yunnan Qujing Hospital

m18017353346@163.com+86 159 0066 3831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026